Patents by Inventor Mark S. Cushman

Mark S. Cushman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Delta-opioid receptor agonists
    Patent number: 11787787
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 17, 2023
    Assignee: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
  • PATIENT SELECTION FOR TREATMENT OF MYC POSITIVE CANCERS WITH INDENOISOQUINOLINES
    Publication number: 20210382058
    Abstract: The present disclosure is directed to a method for selecting a patient with cancer for treatment with a compound of formula (I) by determining if the patient's cancer cells are MYC-positive and when the MYC promoter sequence in those cancer cells contains a nucleic acid sequence capable of forming a MYC G-quadruplex (MYC G4) (i.e. are MYC G4-positive) and treating the patient with a compound of formula (I).
    Type: Application
    Filed: May 28, 2021
    Publication date: December 9, 2021
    Inventors: Mark S. Cushman, Danzhou Yang, Guanhui Wu, Kaibo Wang
  • DELTA-OPIOID RECEPTOR AGONISTS
    Publication number: 20210155614
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 27, 2021
    Applicant: Purdue Research Foundation
    Inventors: Richard M. Van Rijn, Mark S. Cushman, Markus Lill, Robert J. Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
  • Delta-opioid receptor agonists
    Patent number: 10954224
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: March 23, 2021
    Assignee: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
  • Azaindenoisoquinoline compounds and uses thereof
    Patent number: 10875860
    Abstract: Tyrosyl-DNA Phosphodiesterases 1 and 2 (Tdp1 and Tdp2) can repair damaged DNA resulting from topoisomerase inhibitors (e.g. Top1) and a variety of other DNA-damaging agents. 7-Azaindenoisoquinolines that are inhibitors of each of Top1, Tdp1 and Tdp2 are disclosed. Also described are methods for preparing azaindenoisoquinoline and methods for treating patients of a cancer using the disclosed azaindenoisoquinoline compounds or a pharmaceutical formulation thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: December 29, 2020
    Assignees: PURDUE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Mark S. Cushman, Ping Wang, Yves George Pommier, Mohamed S. A. Elsayed
  • Aza-A-ring indenoisoquinoline topoisomerase I poisons
    Patent number: 10759795
    Abstract: The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer in mammals using the described aza-A-ring indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: September 1, 2020
    Assignees: PURDUE RESEARCH FOUNDATION, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Mark S. Cushman, Daniel E. Beck, Yves Pommier
  • NOVEL DELTA-OPIOID RECEPTOR AGONISTS
    Publication number: 20200199111
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 25, 2020
    Applicant: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
  • AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20200095243
    Abstract: Tyrosyl-DNA Phosphodiesterases 1 and 2 (Tdp1 and Tdp2) can repair damaged DNA resulting from topoisomerase inhibitors (e.g. Top1) and a variety of other DNA-damaging agents. 7-Azaindenoisoquinolines that are inhibitors of each of Top1, Tdp1 and Tdp2 are disclosed. Also described are methods for preparing azaindenoisoquinoline and methods for treating patients of a cancer using the disclosed azaindenoisoquinoline compounds or a pharmaceutical formulation thereof.
    Type: Application
    Filed: December 19, 2017
    Publication date: March 26, 2020
    Inventors: Mark S. Cushman, Ping Wang, Yves George Pommier, Mohamed S.A. Elsayed
  • AZA-A-RING INDENOISOQUINOLINE TOPOISOMERASE I POISONS
    Publication number: 20190382401
    Abstract: The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer in mammals using the described aza-A-ring indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: March 15, 2017
    Publication date: December 19, 2019
    Applicant: Purdue Research Foundation
    Inventors: Mark S. CUSHMAN, Daniel E. BECK, Yves POMMIER
  • Phenylthiazoles and uses thereof
    Patent number: 10414759
    Abstract: Series of 2-phenyl-4-methylthiazole analogs are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant Straphylococcus aureus (MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 17, 2019
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Abdelrahman S. Mayhoub, Mohamed Seleem
  • PRODRUGS OF ANTICANCER AGENTS INDOTECAN AND INDIMITECAN
    Publication number: 20190218226
    Abstract: Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of anticancer agents. The present invention discloses series of prodrugs of two indenoisoquinoline compounds currently in clinical trials as a potential treatment for cancers.
    Type: Application
    Filed: February 3, 2017
    Publication date: July 18, 2019
    Inventors: Mark S. Cushman, Pengcheng LV
  • PHENYLTHIAZOLES AND USES THEREOF
    Publication number: 20180319784
    Abstract: Series of 2-phenyl-4-methylthiazole analogues are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant Straphylococcus aureus (MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 8, 2018
    Applicant: Purdue Research Foundation
    Inventors: Mark S. Cushman, Abdelrahman S. Mayhoub, Mohamed Seleem
  • Triphenylethylene compounds and uses thereof
    Patent number: 9845295
    Abstract: Triphenylethylene compounds of formula (II) as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 19, 2017
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Mark S Cushman, Wei Lv, Li-Ming Zhao
  • ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY
    Publication number: 20170267667
    Abstract: The invention disclosed herein pertains to compounds of alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of patients with acquired-immune deficiency syndrome (AIDS). Also described are methods for treating AIDS patients using the described alkenyldiarylmethane compounds.
    Type: Application
    Filed: March 15, 2017
    Publication date: September 21, 2017
    Applicant: Purdue Research Foundation
    Inventors: Mark S. Cushman, Takeshi Sakamoto
  • TRIPHENYLETHYLENE COMPOUNDS AND USES THEREOF
    Publication number: 20170144975
    Abstract: Triphenylethylene compounds as dual aromatase inhibitors and selective estrogen receptors modulators are described. Also described are methods for treating patients of breast cancers, and patients of breast cancer comorbid with osteoporosis, using the described triphenylethylence compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 25, 2017
    Inventors: Mark S. Cushman, Wei Lv, Li-Ming Zhao
  • DUPA-INDENOISOQUINOLINE CONJUGATES
    Publication number: 20160367685
    Abstract: A targeting ligand-cytotoxic drug conjugate, for example, a DUPA-Indenoisoquinoline conjugate, is useful for treating cancers, e.g., prostate cancer.
    Type: Application
    Filed: November 5, 2014
    Publication date: December 22, 2016
    Inventors: Mark S. Cushman, Phillip S. Low, Trung X. Nguyen
  • Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors
    Patent number: 9402842
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: August 2, 2016
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves George Pommier
  • N-substituted indenoisoquinolines and syntheses thereof
    Patent number: 9399660
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 26, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Yves George Pommier, Peng-Cheng Lu, Christophe Marchand, Keli Agama
  • N-substituted indenoisoquinolines and syntheses thereof
    Patent number: 9388211
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 12, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves George Pommier, Smitha Antony, Keli K. Agama, Daniel E. Beck
  • Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
    Patent number: 9328073
    Abstract: The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: May 3, 2016
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Yves George Pommier